Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
P/E ratio for Aadi Bioscience, Inc. (AADI)
P/E ratio as of 2023: -0.83
According to Aadi Bioscience, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.83. At the end of 2022 the company had a P/E ratio of -5.07.
P/E ratio history for Aadi Bioscience, Inc. from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.83 |
| 2022 | -5.07 |
| 2021 | -1.96 |
| 2020 | -0.72 |
| 2019 | -1.09 |
| 2018 | -5.55 |
| 2017 | -4.81 |
| 2016 | -9.56 |
| 2015 | -9.51 |
| 2014 | -5659.04 |
| 2013 | -5935.33 |
| 2012 | -5974.63 |
| 2011 | -7252.52 |
| 2010 | -20093.77 |
| 2009 | 0.00 |
| 2008 | 0.00 |